Infections in cancer patients. Results with gentamicin sulfate therapy.
about
Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaA novel use of gentamicin in the ROS-mediated sensitization of NCI-H460 lung cancer cells to various anticancer agentsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trialsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.Mezlocillin for treatment of infections in cancer patientsPotential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patientsEffects of cytotoxic and immunosuppressive agents on the immune system.Human pharmacology of 6-[D-alpha-(3-guanylureido)-phenylacetamido]-penicillanic acid (BL-P1654).Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycinSynergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.Infections caused by gram-negative pathogens: new clinical considerations.Ticarcillin therapy of infections.Leukocyte transfusions for the prophylaxis and treatment of infections associated with granulocytopenia.Combination therapy for treatment of infections with gram-negative bacteria.Mezlocillin: in vitro studies of a new broad-spectrum penicillin.Azlocillin: in vitro studies of a new semisynthetic penicillin.Pharmacology and efficacy of netilmicin.Piperacillin: in vitro evaluationPseudomonas aeruginosa infection in cancer patients.The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review.Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia.Controversies in the management of febrile neutropenic cancer patients.Antibacterial and immunostimulatory properties of chemotactic N-formyl peptide conjugates of ampicillin and amoxicillin.Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro modelIn vitro model simulating the form of exposure of bacteria to antimicrobial drugs encountered in infection.Empiric treatment of fever in acute leukaemia with tobramycin-cephalothin, and the escape clause provision of corticosteroids.Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension?Comparative study of three routes of administration of sisomicin.
P2860
Q24201767-CACC6A2D-67F6-4482-A367-08FE7C13AFD6Q24248048-04D7313A-65EE-4FD4-814D-0FFD32B6A42AQ28393238-118582B1-3DD8-4F31-8190-D6C475E59B69Q30756968-EFD79298-1D2B-455E-AF30-A7FADAA29449Q31143077-0E36423E-5ABF-405C-8D55-E955D828F0D6Q33730391-B2C99A0A-B747-44CC-985F-F715052EF741Q33731809-BEBCC358-57F0-4227-AC41-B017B9C944E5Q34072063-524EA52F-0DF5-4DA1-9C3B-CD15E15182D4Q34904238-42AFEA3C-0191-4FA7-A83B-2432D3216670Q34928940-BA145B63-12BD-4362-8436-886A3DE14047Q34981359-1F69907E-37AA-40A3-BDAF-BEE357FED405Q35540674-785833DC-A81E-4F9C-8831-7EA0A8FC8411Q35541847-BEA4FCF0-856F-41B4-BEB2-10882E2B5F91Q35653667-DF8074BC-A1E0-4DBA-A3F6-99B0A1B3F1C8Q35816439-248BE85F-05BE-42EB-BD81-D2C0D52119D6Q36156077-76132D30-8AEF-4E7D-B590-C1239A3250A7Q36458437-93BE39AE-CC00-46A3-9580-2DEFFED0A748Q36462997-E410E898-04F3-4985-999E-C88A79DC06FBQ36469912-882BB82B-78F8-45E5-AD35-99E447A83310Q36472026-F31929BF-673F-4BD6-B453-842384C142D7Q36756527-D27B1152-FF54-461D-822A-7098FCC27EDFQ37969132-3116E74A-6B78-4A53-829F-688C04061DF1Q39261281-F56E55C1-1939-459A-B9C4-976198B63071Q39603225-88988944-4CCB-44C7-977A-717FD161E17FQ39819887-CE1B4183-3817-4575-895E-7E354A33933CQ39833928-A439DCD5-16DD-4DAB-AE33-6820AEA236D6Q40620708-CA9432AF-3F9E-4ECB-8A88-D07D36C0AAD5Q40864054-51B0DF9A-B7AB-42AC-9696-B3684DAF5F73Q41091116-2AA3AA15-CDBE-43C6-9241-85B84E71969FQ41348034-2AB96680-9629-46A0-AAB7-BB08E97D1201Q43638326-2BCE706B-8C03-4062-B74A-A5093C6F47A9
P2860
Infections in cancer patients. Results with gentamicin sulfate therapy.
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年学术文章
@wuu
1972年学术文章
@zh-cn
1972年学术文章
@zh-hans
1972年学术文章
@zh-my
1972年学术文章
@zh-sg
1972年學術文章
@yue
1972年學術文章
@zh
1972年學術文章
@zh-hant
name
Infections in cancer patients. Results with gentamicin sulfate therapy.
@en
Infections in cancer patients. Results with gentamicin sulfate therapy.
@nl
type
label
Infections in cancer patients. Results with gentamicin sulfate therapy.
@en
Infections in cancer patients. Results with gentamicin sulfate therapy.
@nl
prefLabel
Infections in cancer patients. Results with gentamicin sulfate therapy.
@en
Infections in cancer patients. Results with gentamicin sulfate therapy.
@nl
P2093
P1433
P1476
Infections in cancer patients. Results with gentamicin sulfate therapy.
@en
P2093
Middleman E
Rodriguez V
Umsawadi T
P304
P356
10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K
P407
P577
1972-06-01T00:00:00Z